David A. Siegel Matinas Bio Pharma Holdings, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$0.67 - $1.51 $203,883 - $459,499	-304,304 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$0.75 - $1.1 $167,775 - $246,070	-223,700 Reduced 42.37%	304,304 $236,000
Q1 2021 May 17, 2021	SELL	$0.96 - $1.74 $50,784 - $92,046	-52,900 Reduced 9.11%	528,004 $554,000
Q4 2020 Feb 16, 2021	SELL	$0.76 - $1.47 $316,161 - $611,522	-416,002 Reduced 41.73%	580,904 $790,000
Q3 2020 Nov 16, 2020	BUY	$0.67 - $0.96 $403,206 - $577,728	601,800 Added 152.31%	996,906 $764,000

Q2 2020 Aug 14, 2020	BUY	$0.52 - $0.92 $152,308 - $269,468	292,900 Added 286.58%	395,106 $305,000
Q1 2020 May 15, 2020	BUY	$0.6 - $2.31 $61,323 - $236,095	102,206 New	102,206 $61,000

25.8M

Ticker MTNB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,864,992
Market Cap $34.7M
Description
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.